Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
01 avr. 2021 06h45 HE
|
BioNTech SE
Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months...
BioNTech und Pfizer geben positive Ergebnisse aus Zulassungsstudie für COVID-19-Impfstoff in Jugendlichen bekannt
31 mars 2021 06h45 HE
|
BioNTech SE
Bei Teilnehmern im Alter von 12-15 Jahren zeigte BNT162b2 sehr hohe Antikörperantworten, die sogar die robusten Antikörperantworten von geimpften 16-25-jährigen Erwachsenen übertrafen und gut...
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
31 mars 2021 06h45 HE
|
BioNTech SE
In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier...
Bone Therapeutics finalise le recrutement et le traitement des patients dans son étude pivot de Phase III évaluant le JTA-004 dans l’arthrose du genou
22 déc. 2020 01h00 HE
|
Bone Therapeutics SA
Principaux résultats attendus au troisième trimestre 2021 Gosselies, Belgique, le 22 décembre 2020, 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie...
Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study
22 déc. 2020 01h00 HE
|
Bone Therapeutics SA
Topline results expected in Q3 2021 Gosselies, Belgium, 22 December 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical...
uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
08 déc. 2020 07h00 HE
|
uniQure Inc.
~ First primary endpoint in study met with mean Factor IX activity of 37% of normal at 26 weeks ~ ~ Data show 91% reduction in reported bleeds requiring treatment, with 87% of patients reporting no...
Pfizer und BioNTech schließen Phase-3-Studie erfolgreich ab: Impfstoffkandidat gegen COVID-19 erreicht alle primären Endpunkte
18 nov. 2020 09h26 HE
|
BioNTech SE
BNT162b2 zeigt in der primären Endpunktanalyse 28 Tage nach der ersten Impfung eine 95%ige Wirksamkeit gegen COVID-19; insgesamt traten 170 bestätigte COVID-19-Fälle auf, mit 162 Fällen in der...
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
18 nov. 2020 07h14 HE
|
BioNTech SE
Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the...
Pfizer und BioNTech geben erfolgreiche erste Zwischenanalyse ihres COVID-19-Impfstoffkandidaten in laufender Phase-3-Studie bekannt
09 nov. 2020 06h45 HE
|
BioNTech SE
Impfstoffkandidat erwies sich in der ersten Zwischenanalyse als mehr als 90 % wirksam im Schutz vor COVID-19-Erkrankung in Probanden ohne nachweisliche vorangegangene SARS-CoV-2-InfektionIn der...
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
09 nov. 2020 06h45 HE
|
BioNTech SE
Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysisAnalysis evaluated...